| Literature DB >> 26726867 |
Artur Jurczyszyn1, Magdalena Olszewska-Szopa2, Vania Hungria3, Edvan Crusoe3, Tomas Pika4, Michel Delforge5, Xavier Leleu6, Leo Rasche7, Ajay K Nooka8, Agnieszka Druzd-Sitek9, Jan Walewski9, Julio Davila10, Jo Caers11, Vladimir Maisnar12, Morie Gertz13, Massimo Gentile14, Dorotea Fantl15, Giuseppe Mele16, David H Vesole17, Andrew J Yee18, Chaim Shustik19, Suzanne Lentzsch20, Sonja Zweegman21, Alessandro Gozzetti22, Aleksander B Skotnicki1, Jorge J Castillo23.
Abstract
Skin infiltration in multiple myeloma (skin MM) is a rare clinical problem. Only a few cases of skin involvement have been reported, primarily in single case reports. We analyzed and present the clinical outcomes, immunohistochemistry and cytogenetic features, and relevant laboratory data on 53 biopsy-proven skin MM cases. The median time from MM diagnosis to skin involvement was 2 years. There appears to be an overrepresentation of immunoglobulin class A (IgA) and light chain disease in skin MM. We found no correlation between CD56 negative MM and skin infiltration. We found that skin MM patients presented in all MM stages (i.e. ISS stages I to III), and there was no preferential cytogenetic abnormality. Patients with skin MM carry a very poor prognosis with a median overall survival (OS) of 8.5 months as time from skin involvement. Moreover, patients with IgA disease and plasmablastic morphology appear to have a worse OS.Entities:
Keywords: Cutaneous; diagnosis; myeloma; skin; treatment
Mesh：
Substances：
Year: 2016 PMID： 26726867 DOI： 10.3109/10428194.2015.1128542
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022